Digital Psychedelia: Hidden Experience and the Challenge of Paranoia somatosphere.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from somatosphere.net Daily Mail and Mail on Sunday newspapers.
Tech Moves: Adaptive Biotech co-founders join life sciences SPAC; new edtech execs; and more
April 15, 2021 at 4:44 pm
Underwritten by
Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: tips@geekwire.com
Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. (Adaptive Biotechnologies Photo) Adaptive Biotechnologies co-founders and brothers Chad and Harlan Robins are among the directors of a new life sciences SPAC.
The blank check company is called CM Life Sciences III Inc. and listed on the NASDAQ starting April 7. The SPAC is targeting companies in “three separate areas of the life sciences industry that are often fragmented life sciences tools, synthetic biology and diagnostics.”
Cybin Inc. Releases Financial Highlights and Provides Business Update
Successful bought deal offering brings total capital raised to-date to approximately $90 million Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines – Adelia Therapeutics acquisition expands scientific team, IP portfolio and diversifies development pipeline Partnership with Kernel provides access to neuroimaging … Successful bought deal offering brings total capital raised to-date to approximately $90 million Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines – Adelia Therapeutics acquisition expands scientific team, IP portfolio and diversifies development pipeline Partnership with Kernel provides access to neuroimaging technology, enabling the potential quantification of psychedelic therapeutics –
Cybin Inc Releases Financial Highlights and Provides Business Update apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “
Transaction”).
Transaction Highlights
Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. Selective modification, through deuteration of psychedelic parent molecules, allows control of the duration of action of these new chemical entities, enabling the design of both short and long-acting treatments.
Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, as well as six patent applications.
Adelia contributes an expanding library of psychedelic derivative drug development candidates. The first lead compounds are expected to enter clinical studies in 2021, subject to receipt of approvals.